FUJIFILM Ransomware Attack
fujifilm.comRansomed
Data has been published on the ransomware group's leak site.
About this victim
Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf
Overview
View group profileDomain
fujifilm.com
Industry
Technology
Country
Japan
Discovered
over 1 year ago
Attack date
Apr 5, 2025
Confidence
100%
Severity
Critical
Status
Data Leaked
Threat group
sarcomaTotal victims
89
First seen
Nov 2025
Last seen
Oct 2026
Group status
active
Sophistication
0
Impact score
70
Threat level
3.8/10Status breakdown
Victim's position within group
Industry
Technology
Known target sector
Country
Japan
Frequently targeted country
Other victims
View all (89)Same group · sarcoma
Group activity
Monthly attacks · sarcoma
89
total · avg 22.3/mo